Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy

BACKGROUND: Patients with metastatic melanoma rely on PD-(L)1 immunotherapy, but only one-third of patients experience treatment response and all initial responders eventually develop resistance. Tumour-derived extracellular vesicles expressing Programmed death ligand 1 (evPD-L1) and soluble Program...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Tara M, Foster, Nathan, Lucien, Fabrice, Markovic, Svetomir, Dong, Haidong, Winters, Jeffrey L, Park, Sean S, Orme, Jacob J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109028/
https://www.ncbi.nlm.nih.gov/pubmed/35551087
http://dx.doi.org/10.1136/bmjopen-2021-050112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109028/
https://www.ncbi.nlm.nih.gov/pubmed/35551087
http://dx.doi.org/10.1136/bmjopen-2021-050112

Ejemplares similares